Clinical trials: Organ Dysfunction Syndrome
Severe Sepsis
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will…
- Trial name
- NCT00386425
- Testing
- Drotrecogin alfa (activated)
- Where
- 47 sites in United States, Belgium and 7 more
- Volunteers
- 486 people
- Sponsor
- Eli Lilly and Company
Sepsis, Multiple Organ Dysfunction Syndrome
Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis
Eligible patients will receive either AP or matching placebo in a double blind, randomized design and following a 2:1 ratio. All medication will be given in addition to standard care for sepsis patients.
- Trial name
- NCT00430859
- Testing
- Alkaline Phosphatase
- Where
- 10 sites in Belgium, Netherlands
- Volunteers
- 37 people
- Sponsor
- AM-Pharma
Multiple Organ Dysfunction Syndrome
Tolerance and Safety of a Duodenal Probe Monitoring the Microcirculation
For Intensive Care Units (ICU) patients, Multiple Organ Dysfunction Syndrome (MODS) is a very common complication yielding high morbidity and mortality.
- Trial name
- MC Monitor (NCT02246036)
- Testing
- APD probe
- Where
- 3 sites in France
- Volunteers
- 10 people
- Sponsor
- Advanced Perfusion Diagnostics
Septic Shock
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Septic shock is a potentially life-threatening condition that can result in multi-organ dysfunction syndrome (MODS) and mortality.
- Trial name
- SSAIL (NCT02317549)
- Testing
- LB1148
- Where
- 34 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Leading BioSciences, Inc
Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac
Studying Complement Inhibition in Complex Cardiac Surgery
The trial enrolls patients undergoing a complex cardiac surgery. The primary goal of the trial is to evaluate the pharmacodynamic dose response relationship of the monoclonal antibody IFX-1 in these patients.
- Trial name
- CARDIAC (NCT02866825)
- Testing
- IFX-1
- Where
- 10 sites in Germany
- Volunteers
- 116 people
- Sponsor
- InflaRx GmbH
Maternal sepsIs
Selective Lipopolysaccharide Hemosorption in Maternal Sepsis
One of the major health problems in the world is sepsis, the number of cases of which, according to WHO, annually reaches 20-30 million. The prevalence and frequency of obstetric sepsis are quite pronounced.
- Trial name
- MINERVA (NCT05711901)
- Testing
- Efferon LPS
- Where
- 7 sites in Russia
- Volunteers
- 30 people
- Sponsor
- Efferon JSC
Cardiac Disease, Multiple Organ Dysfunction Syndrome
Efferon LPS Hemoadsorption in Cardiac Surgery Patients
This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass…
- Trial name
- NCT07532174
- Testing
- Efferon LPS
- Where
- 3 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Efferon JSC
Severe Sepsis, Septic Shock
Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection.
- Trial name
- SCIENS (NCT02246595)
- Testing
- CaCP29
- Where
- 11 sites in Germany
- Volunteers
- 72 people
- Sponsor
- InflaRx GmbH
Severe Sepsis, Septic Shock
Adrenomedullin and Outcome in Severe Sepsis and Septic Shock
The aim of this prospective study is to assess the prognostic value of bioactive plasma adrenomedullin (ADM) in 600 patients with severe sepsis or septic shock in an international multicenter study and to validate the findings…
- Trial name
- AdrenOSS (NCT02393781)
- Where
- 24 sites in Belgium, France and 3 more
- Volunteers
- 596 people
- Sponsor
- Sphingotec GmbH
Cardiac Disease, Multiple Organ Dysfunction Syndrome
Hemoperfusion Efferon LPS During Cardiac Surgery Using Cardiopulmonary Bypass
More than 1 million people undergo cardiac surgery each year worldwide. Cardiac surgeries still in most cases require cardiopulmonary bypass, use of myocardial protection against aortic clamping and creation of cardioplegic…
- Trial name
- NCT06659289
- Testing
- Efferon LPS
- Where
- Russia
- Volunteers
- 14 people
- Sponsor
- Efferon JSC
Organ Dysfunction Syndrome Sepsis
Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS
The trial evaluates the safety and efficacy of one and two doses of the study drug, Allocetra-OTS, in patients who have been diagnosed with sepsis.
- Trial name
- P-SOFA-1 (NCT03925857)
- Testing
- Allocetra-OTS
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Enlivex Therapeutics Ltd.
Female Urogenital Diseases, Urinary Incontinence
Clinical Trial of "Magic Gyno" Laser Device
The aim of this prospective study is investigation of efficiency and safety of medical device "Magic Gyno" in accordance with the stated purpose.
- Conditions
- Female Urogenital Diseases, Urinary Incontinence, Prolapse Genital, Menopausal Syndrome
- Trial name
- NCT05463081
- Testing
- Laser treatment, Blood test, Clinical urine test
- Where
- Russia
- Volunteers
- 70 people
- Sponsor
- MeLSyTech, Ltd
Sepsis, Septic Shock
Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis
The purpose of this prospective, non-interventional, multi-centre clinical study is to assess the clinical validity of the Heparin Binding Protein (HBP) assay for indicating the presence, or outcome, of severe sepsis (including…
- Conditions
- Sepsis, Septic Shock, Sepsis With Acute Organ Dysfunction
- Trial name
- NCT03113721
- Where
- 5 sites in United States
- Volunteers
- 571 people
- Sponsor
- Axis Shield Diagnostics Ltd